Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release Semaglutide USA supplier its latest quarterly report later this week. Experts are predicting strong performance driven by the robust sales of Lilly's blockbuster drugs, particularly recent launches. However, there are also concerns about potenti